Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placento+ is a brand of human placenta extract (HPE) primarily utilized in aesthetic medicine and regenerative therapy. Derived from human placental tissue, it consists of a complex mixture of bioactive components, including growth factors such as hepatocyte growth factor (HGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF), as well as amino acids, vitamins, and minerals. The product is typically administered via intramuscular or subcutaneous injection to promote skin rejuvenation, wound healing, and anti-aging effects. Its mechanism of action involves the stimulation of fibroblast proliferation, enhancement of collagen and elastin synthesis, and modulation of inflammatory responses. While human placenta extracts are regulated as pharmaceutical biologics in certain jurisdictions (e.g., Japan and India) for conditions like hepatic cirrhosis and menopausal symptoms, Placento+ is frequently marketed for cosmetic improvements and is registered as a pharmaceutical product in several Southeast Asian markets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human placenta extract.